Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.
Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.
While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.
Bone Biologics Corp Completes Financing With Hankey Capital, LLC
EDISON, N.J., May 6, 2015 -- Bone Biologics, Corp., ("Bone Biologics") announced today the completion of a $2M funding round with Hankey Capital, LLC ("Hankey Capital") of Los Angeles, CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1) for use with patients undergoing spinal fusion.
Michael Schuler, CEO of Bone Biologics noted, "We are pleased with the completion of this round of funding which will allow the company to continue process development leading to the manufacturing of Nell-1 in preparation for human clinical trials to validate the technology in regenerative medicine for bone."
NELL-1, a bone growth factor has been developed by Bone Biologics in partnership with University of California, Los Angeles (UCLA) and the Musculoskeletal Transplant Foundation (MTF) as a more specific alternative to other bone growth factors used in health care today. In large animal studies, NELL-1 exhibited none of the side effects currently associated with other bone growth factors including ectopic bone growth, extraneous bone growth or cyst formation. The next phase will be completing the development and testing work needed to seek regulatory approval for the initial pilot study in human clinical trials.
Bone Biologics Board Chairman Bruce Stroever stated, "We are very pleased that funding has been secured to supplement the initial funding provided by MTF. This brings to $7 million the total funding to date from Hankey Capital and we are pleased with their increased commitment to this exciting venture. The technology discovered by UCLA and being developed by Bone Biologics has the potential to make a significant difference in patient's lives, dramatically improving spinal fusion, while controlling healthcare costs." Mr. Stroever is the President and CEO of MTF.
About Bone Biologics
Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation's leading tissue bank and Orthofix a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA. Visit: www.bonebiologics.com
The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than five million grafts for transplantation. For more information visit: www.mtf.org
About Hankey Capital, LLC
Hankey Capital, LLC, a member of the Hankey Group of Companies, is a private equity firm based in Los Angeles, California. The Hankey Group of Companies is one of the largest subprime auto finance lending organizations in the United States and provides a broad array of equity and debt capital solutions to emerging growth companies as well as origination and management of a $300MM auto and real estate asset-based finance portfolio.
This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "will," "will be," "anticipate," "predict," "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form S-1/A, filed with the Securities and Exchange Commission on April 30, 2015. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
For information regarding our company and/or products, please complete the form below.